Business Wire

Federal Court Dismisses Roku Lawsuit Against Access Advance, Declines to Set Global Patent Pool Pricing

Share

Access Advance LLC today announced that the US District Court for the District of Massachusetts has dismissed a lawsuit filed by Roku Inc. seeking to compel the Court to set a global fair, reasonable and non-discriminatory (FRAND) royalty rate for the HEVC Advance Patent Pool. Judge Richard G. Stearns determined that his Court "lacks jurisdiction to determine" a global FRAND royalty rate, noting that the “US patents constitute only a fraction of a larger portfolio.” The Court further concluded that its “opinion on the appropriate royalty rate would merely be advisory”, which is prohibited under US law.

Court Reinforces Limits on Judicial Intervention

In December 2024, Roku sued Access Advance LLC, along with patent pool licensors Dolby Laboratories Inc. and Sun Patent Trust, in the District of Massachusetts seeking judicial determination of whether any of the numerous offers the Defendants made to Roku for three separate licenses to global patent portfolios – including the HEVC Advance Patent Pool containing more than 27,500 patents owned by dozens of non-parties to the litigation and issued in 117 different countries and territories – were FRAND, and if it was not, then to set a worldwide FRAND rate. Roku’s Massachusetts complaint raised issues already pending for months in three cases involving the same licensors before the European Unified Patent Court (“UPC”) in Germany. By seeking a second opinion from the Massachusetts Federal Court, Roku attempted to circumvent the UPC’s determination of these same questions, forum shop to address the same or similar disputes in multiple venues, and obtain from the Massachusetts Federal Court an opinion on license terms.

In its order dismissing the lawsuit, Judge Stearns determined that the Court does not have jurisdiction to set a global FRAND rate as requested by Roku. The dismissal also effectively precludes any conflict between the Massachusetts lawsuit and the UPC actions well underway in Europe.

Strategic Implications for Industry

The dismissal signals to potential licensees that the rule of law matters, and litigation is not a tool to avoid good-faith licensing negotiations. It reinforces the notion that patents are territorial and that US courts cannot be used as a vehicle to unilaterally set global FRAND royalty rates for patents held by non-parties in lieu of negotiations.

"This is a significant ruling that confirms what we've long understood about the complexities of global patent licensing," said John Kinton, Chief Legal Officer at Access Advance. "We appreciate the court's careful consideration of the jurisdictional challenges involved when dealing with patent portfolios that span more than a hundred countries and involve dozens of patent owners who aren’t parties to the litigation."

The Roku decision is consistent with the decisions to date in ongoing litigation in the United Kingdom, where Tesla is appealing the UK Appeals Court’s affirmance of the UK Patents Court’s denial of Tesla’s attempt to obtain worldwide FRAND rates for the Avanci patent pool, which does not own any UK patents.

The decision adds to a growing body of cases in which national courts are reluctant to set worldwide FRAND rates absent agreement from the parties. This is expected to maintain stability in standards essential patent licensing and encourage good-faith participation in SEP pool licensing negotiations.

About Access Advance: Access Advance LLC is an independent licensing administrator company formed to lead the development, administration, and management of patent pools for licensing essential patents of the most important video codec technologies. Access Advance provides a transparent and efficient licensing mechanism for both patent owners and patent implementers.

Access Advance manages and administers the HEVC Advance Patent Pool for licensing over 27,500 patents essential to H.265/HEVC technology and the VVC Advance Patent Pool for licensing essential patents to VVC/H.266 technology. The company's Multi-Codec Bridging Agreement provides eligible licensees with a single discounted royalty rate structure for licensees participating in both the HEVC Advance and VVC Advance pools. In addition, Access Advance offers the VDP Pool, a comprehensive licensing solution for video streaming services covering HEVC, VVC, VP9, and AV1 codecs. For more information, please visit: www.accessadvance.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250728008648/en/

Contacts

Media:
Meredith Hollander
Director, Strategic Communications
Access Advance LLC
Email: press@accessadvance.com
Website: www.accessadvance.com -
https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.accessadva
nce.com&esheet=54297666&newsitemid=20250728008648&lan=en-US&anchor=www.accessadv
ance.com&index=2&md5=85e782e0c6d76357f8be72231b52818e

Licensing Inquiries:
Email: licensing@accessadvance.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Phase 1 Results for its TGFβR2×PD-1 Bispecific Antibody in Advanced Colorectal Cancer and KRAS G12D Inhibitor in Advanced Pancreatic Ductal Adenocarcinoma19.10.2025 20:30:00 EEST | Press release

Incyte (Nasdaq:INCY) announced the first clinical data evaluating its TGFβR2×PD-1 bispecific antibody (INCA33890) for patients with microsatellite stable (MSS) colorectal cancer; and its potent, selective and orally bioavailable KRAS G12D inhibitor (INCB161734) for patients with KRAS G12D mutations, specifically pancreatic ductal adenocarcinoma (PDAC). The data were featured in two oral sessions (Investigational immunotherapy; Abstract #1522MO and Developmental therapeutics; Abstract #916O, respectively) at the European Society of Medical Oncology (ESMO) Congress 2025. “The proof-of-concept data highlight the potential of INCA33890 and INCB161734 to address significant medical needs in patients with advanced solid tumors, including MSS colorectal cancer and PDAC,” said Pablo J. Cagnoni, M.D., President and Head of Research and Development, Incyte. “These results, including the favorable safety profiles as monotherapies, support continued clinical development. We look forward to explori

Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment19.10.2025 12:15:00 EEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today shared new late-breaking data from its pivotal Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer at the European Society for Medical Oncology (ESMO) 2025 Annual Meeting. The data demonstrated a progression-free survival (PFS) benefit for patients who experienced disease progression while on or after taking a PARP inhibitor (PARPi), a patient population with particularly poor prognosis. The presentation slides can be found here. The company also announced expansion of the Phase 2 BELLA trial in a poster session at ESMO, found here. New relacorilant data presented at ESMO demonstrated a consistent benefit in PARPi subgroups to overcome chemotherapy resistance. Relaco

Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA ™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 14:00:00 EEST | Press release

Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the durable benefit that vimseltinib can offer patients.” Summary of Data and Findings from the 2-year results of the MOTION Phase

ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 17:09:00 EEST | Press release

ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui

Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 17:00:00 EEST | Press release

Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the study increased considerably to 76.2% (95% CI: 63.8, 86.0) by blinded independent review committee (BICR) per RECIST v1.1, from 54% at Week 25. The study also showed continued clinically meaningful improvements in key secondary endpoints related to patient outcomes such as pain and function. The safety profile was consistent with previously reported data. The results are being presented today in the Sarcoma mini-oral session at the European Society for Medical

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye